(2/4)Treated w 4 cycles gem-cis, followed by y90 and consolidative high dose hypofractionated XRT (a/w improved survival compared to conventional XRT by @haydencrane5 and Randa Tao). Lower dose PTV’s on edge to maintain normal tissue. 60-67.5 Gy/15 fx to center. higher better.
(4/4) PET scan negative for residual disease too. Will follow. Integration of multidisciplinary care and access to new technology can open doors. Grateful to the brave patients who have walked this path, amazed to see what they can accomplish in treatment and in life.
(3/4)Now over 2 years from treatment with no radiographic evidence of residual disease. Intact liver function and excellent performance status. Fortunate to work with excellent colleagues in medical oncology, interventional radiology, and hepatobiliary surgery @ClevelandClinic.
(1/4)As Cholangiocarcinoma awareness month draws to close wanted to point out aggressive multi-disciplinary treatment offers opportunity for success w unresectable CCA. 18 cm tumor w outflow obstruction resulting in aborted trisegmentectomy due to unstable BP and liver bleeding.
The @ClevelandClinic 14th Annual International Symposium on #SBRT and #SRS will be held February 25-27, 2022, bringing together world leaders in brain, spine and body-targeted stereotactic radiation modalities and techniques. Join us! https://t.co/5zj14tc5pJ
New publication with @jihyunRadOnc. 🌟Our observations suggest that early antiarrhythmic effects after cardiac radioablation result from conduction disturbances and membrane potential alterations without necrosis. (https://t.co/CAvdmibgv5)
I did a thing today...I volunteered to give vaccines with the Cuyahoga County Health Dept and the Medical Reserve Corps. It felt great to help move us forward in the fight against COVID19.
Excellent review article in Seminar of Radiation Oncology by @danielrgomez44 about consolidative thoracic radiotherapy in oligometastatic lung cancer
#radonc https://t.co/ZI9wyEuOzm
Prospective contour review takes effort, but @DrAndrewVassil has that covered. Great to work with colleagues who go the extra mile every day. #PatientSafetyAwarenessWeek
Full publication of randomised Scandinavian dose escalation trial for LS SCLC
45Gy / 30 Fx / 3 weeks vs 60Gy / 40 Fx / 4 weeks
⬆️ 2a OS 74.2% vs 48.1%
⬆️ Med OS 37.2 mo vs 22.6 mo
↗️ Med PFS 18.6 mo vs 10.9 mo (p=0.13)
➡️ Grade 3+ toxicity and SAEs
#radonc
https://t.co/546Mzdoip2
@ndesai2005@Issarami@RTendulkarMD@DrSpratticus Innovative clinical trial by @ndesai2005 randomizing low/intermediate risk prostate cancer to +/- nerve sparing to quantify impact on QOL and cancer outcomes post treatment. Open at UTSW, CCF, Penn, U Colorado and more.
Great summary for role of adjuvant versus salvage XRT is important for our patients with biochemical recurrent #prostatecancer - @felixfeng with 22-gene classifier from @NRGonc RTOG 9601 trial that may help us define high risk populations needing ADT. @ASCO#GU21